In today’s briefing:
- Smartkarma Webinar | High Conviction Trade Ideas in the US
- Quiddity Leaderboard ASX Sep 23: Potential Surprises and Final Thoughts
- Actinogen Medical – Funding the next stage of Xanamem development
- Centene Corporation: Does It Have A Sustainable Competitive Advantage? – Key Drivers
Smartkarma Webinar | High Conviction Trade Ideas in the US
- In the next installment of our Webinar series, we go live with Smartkarma Insight Provider Andrei Zakharov
- He will be discussing some U.S. SaaS stocks, crypto mining companies as part of his High Conviction Trade Ideas in the US.
- He will also be sharing his insights into his high-conviction trade idea in biotech – oncology-focused company, Revolution Medicines.
The webinar will be hosted on Wednesday, 14 August 2023, 17:00 SGT/HKT.
Andrei Zakharov is the founder of independent equity research firm Algosun Global Limited, with broad professional experience at leading multinational banks Citibank and Morgan Stanley. Andrei has a respectable background in wealth advisory services for UHNW individuals, alternative energy buy-side research, in-depth analysis of pre-IPO technology unicorns, and portfolio management.
Quiddity Leaderboard ASX Sep 23: Potential Surprises and Final Thoughts
- In this insight, we take a look at the potential index changes for ASX 300, 200, 100, 50, and 20 in the September 2023 Rebalance.
- I expect one change for ASX 100 and 3 ADDs and 4 DELs for ASX 200. There could be 11 ADDs and 9 DELs for ASX 300.
- ASX 300 member Leo Lithium (LLL AU) is currently suspended from trading and that could have interesting implications for the stock’s ASX 300 membership.
Actinogen Medical – Funding the next stage of Xanamem development
Actinogen recently provided a Q423 quarterly update summarising that its two development programmes for lead candidate Xanamem remain on track, with the Phase IIb XanaMIA study portion assessing the drug in lead indication Alzheimer’s disease (AD) still scheduled to start in H2 CY23, with results still expected in H2 CY25. For the company’s XanaCIDD study in patients with cognitive impairment (CI) associated with major depressive disorder (MDD), enrolment is approaching 25% and the company continues to expect results in H1 CY24 as it is opening new US-based study sites to compensate for regulatory delays in the UK. The company reported a 30 June cash position A$8.46m and has announced a A$10m rights offering allowing existing shareholders to purchase up to 400m shares at A$0.025 per share. After rolling forward our estimates, our pre-financing valuation adjusts slightly to A$645m, or A$0.36/share, versus A$640m (A$0.35/share) previously. Overall, we view the financing as a positive and necessary step to continue Xanamem development.
Centene Corporation: Does It Have A Sustainable Competitive Advantage? – Key Drivers
- Centene Corporation managed to exceed analyst expectations in terms of revenue as well as earnings.
- For the quarter, they increased their expectation for 2023 premium and service revenue by an additional $1.8 billion.
- The commercial HBR met the company’s expectations, considering the quarter’s 200,000 new members and the marketplace’s ongoing robust growth.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
